List view / Grid view
Neutrons, electrically neutral particles found within the nucleus of the atom, are coming into their own in the exploration of new ways to get drugs to their targets. Neutron techniques are being used to investigate innovative new approaches to drug delivery that could increase the effectiveness of treatments, improve the…
Macrocyclic compounds (see Figure 1) have fascinated medicinal chemists for generations. The first ones which have been characterised are the naturally occurring cyclodextrins (CDs), cyclic oligomers of glucose, which can be obtained by bacterial synthesis from starch. Calixarenes (CXs) were among the first man-made macrocycles, followed by crown ethers (Pedersen,…
The use of monoclonal antibodies and antibody-based molecules as therapeutics to treat patients suffering with severe disease has become a major success story. Due to the exquisite specificity with which they interact with their antigen and the fact that their large binding surface can intervene at sites and targets not…
15 July 2014 | By BioStrata
For those that couldn’t attend, here is a summary of some of the interesting insights shared at ELRIG’s recent Robotics and Automation 2014 Conference.
The ubiquitin-proteasome system (UPS) is a hierarchical enzymatic cascade that plays an essential role in a broad range of cellular pathways and is found in cytoplasmic and nuclear actions of all eukaryotic cells...
Heat shock proteins (HSPs) have been proposed as therapeutic targets for novel anticancer agents. However, candidates have thus far failed due to low tolerability, limiting their efficacy. This failure highlights our current inability to predict drug toxicity in patients, a Holy Grail in modern drug discovery. Paradoxically, the fundamental role…
In November 2013, the US Food and Drug Administration (FDA) allowed for the first time the marketing of high-throughput DNA sequencing technology for diagnostic testing. It was a breakthrough year for Next Generation Sequencing (NGS)...
Developments over the past decade have demonstrated that non-coding RNAs can exert control of transcriptional gene expression. Recent advances in genome-wide studies have revealed an abundance of long non-coding RNAs (lncRNAs) in human cells, which are as numerous as protein-coding genes...
9 May 2014 | By Guido Rasi, Professor Sir Mark Pepys, Kenji Schorpp et al.
We are delighted to welcome you to the inaugural issue of European Drug Target Review, a magazine focused on the changing landscape of the drug discovery industry...
7 May 2014 | By Kevin V. Morris, Bhupinder Bhullar
In this Genomics In-Depth Focus: Kevin V. Morris discusses the therapeutic potential of RNA directed epigenetic regulation of transcription, and Bhupinder Bhullar looks at drug resistance mechanisms and target selection in disease treatment strategies...
7 May 2014 | By Kenji Schorpp, Christophe Antczak, Balajee Somalinga, Hakim Djaballah
In this Screening In-Depth Focus: Kenji Schorpp looks at targeting the ubiquitin-proteasome system, and experts from Memorial Sloan-Kettering Cancer Center discuss a high content assay opportunity to measure cellular stress response using heat shock proteins...
Over the past few years, the landscape of medicines development has shifted. We have seen a decline in the research and development productivity of the pharmaceutical industry. Innovator drug developers have been confronted with the current pressure on healthcare budgets, as well as a wave of patent expiries for blockbuster…
Although this target class is already heavily investigated, there are still a significant number of opportunities for discovery of novel drugs targeting additional GPCRs. In this review, scientists from AstraZeneca R&D discuss the general build-up of GPCR screening cascades for discovery of chemical leads that can be further developed into…
Clearly what is needed is a synergistic collaboration bringing together the respective competence and expertise of academia and industry. All the major pharmaceutical companies have recognised this need and have introduced a range of different models for association with academia and small biotech or biopharma companies. Attempted solutions range from…
The ability to individualise a patient’s care has become a particularly pressing issue in the field of cancer therapeutics as there is a growing recognition that both the global incidence of cancer is steadily rising and the associated costs in terms of treatment and lost productivity are ever increasing. Advances…
